证券代码：603716 证券简称：塞力医疗 公告编号：2025-052 塞力斯医疗科技集团股份有限公司 2025年第三次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 6 月 20 日 (二)股东大会召开的地点：公司（武汉市东西湖区金山大道 1310 号）A 栋 C 会 议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 727 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 34,343,527 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 18.3616 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由塞力斯医疗科技集团股份有限公司董事会召集，由公司董事 长温伟先生主持。本次会议的召集、召开、表决方 ...

国浩律师（上海）事务所 关 于 塞力斯医疗科技集团股份有限公司 2025 年第三次临时股东大会 之 法律意见书 上海市静安区山西北路 99 号苏河湾中心 25-28 楼 邮编：200085 25-28th Floor, Suhe Centre, No.99 West Shanxi Road, Shanghai 200085, China 电话/Tel:+86 21 5234 1668 传真/Fax:+86 21 5243 3320 网址/Website: http://www.grandall.com.cn 2025 年 6 月 国浩律师（上海）事务所 法律意见书 国浩律师（上海）事务所 关于塞力斯医疗科技集团股份有限公司 2025 年第三次临时股东大会之法律意见书 本所律师根据《中华人民共和国公司法》《中华人民共和国证券法》（以 下简称"《证券法》"）等法律、法规及《上市公司股东会规则》和《塞力斯 医疗科技集团股份有限公司章程》（以下简称"《公司章程》"），就本次股 东大会的召集、召开程序、出席大会人员资格、会议表决程序等事宜发表法律 意见。 为出具本法律意见书，本所律师出席了本次股东大会，审查了公司提供的 ...

"聪明钱"流向曝光！暗盘资金破解主力操盘密码>> 创新药概念延续涨势，塞力医疗（603716）逼近涨停，新开源（300109）、昂利康（002940）、联化科 技（002250）、众生药业（002317）、睿智医药（300149）等集体高开。 ...

6月10日，塞力医疗今日收盘13.46元，上涨9.97%，最新市净率3.03，创59天以来新低，总市值25.71亿 元。 来源：金融界 塞力斯医疗科技集团股份有限公司的主营业务是体外诊断试剂、体外诊断仪器的销售业务。公司的主要 产品是单纯销售、集约化IVD、集约化SPD。公司较早将IVD集约化业务升级布局SPD运营业务，取得 先发优势。同时基于公司早些年强大的IVD运营根基，凭借医疗供应领域二十余年的经验累积和过硬实 力荣登中国物流与采购联合会医疗器械供应链50强获奖企业名单，同时被授予《医药产品医院院内物流 服务规范》团体标准试点单位。 最新一期业绩显示，2025年一季报，公司实现营业收入2.87亿元，同比-40.75%；净利润-14320949.69 元，同比-553.66%，销售毛利率23.60%。 截至2025年一季报，共有7家机构持仓塞力医疗，其中QFII4家、其他3家，合计持股数4042.93万股，持 股市值4.19亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)2塞力医疗-11.34-12.293.0325.71亿行业平均 45.2434.022.09112.61亿行业中值28.5 ...

Market Overview - The Shanghai Composite Index closed at 3384.82 points, below the five-day moving average, with a decline of 0.44% [1] - The total trading volume of A-shares reached 14,514.37 million yuan [1] Stocks Performance - A total of 219 A-shares broke through the five-day moving average today [1] - Stocks with significant deviation rates include: - Huaguang Yuanhai with a deviation rate of 20.27% and a daily increase of 26.88% [1] - Shuguang Shuchuang with a deviation rate of 15.32% and a daily increase of 24.01% [1] - Haooubo with a deviation rate of 12.92% and a daily increase of 20.00% [1] - Stocks with smaller deviation rates that just crossed the five-day moving average include: - Dongfang Precision, Zijin Bank, and Chuanheng Co., with minor deviation rates [1]

Market Overview - The Shanghai Composite Index closed at 3403.52 points, above the five-day moving average, with a slight increase of 0.11% [1] - The total trading volume of A-shares reached 808.39 billion yuan [1] Stocks Performance - A total of 253 A-shares have surpassed the five-day moving average today [1] - Notable stocks with significant deviation rates include: - Shuguang Digital (14.08% deviation) - Sun Cable (8.01% deviation) - Suqian Liansheng (7.42% deviation) [1] Top Gainers - The top gainers today include: - Shuguang Digital: 22.27% increase, latest price at 61.87 yuan - Sun Cable: 10.00% increase, latest price at 6.82 yuan - Suqian Liansheng: 10.00% increase, latest price at 9.90 yuan [1] Additional Notable Stocks - Other stocks with notable performance: - Celery Medical: 9.97% increase, latest price at 13.46 yuan - Zhongke Shuguang: 10.00% increase, latest price at 68.09 yuan - Yuanwang Valley: 9.97% increase, latest price at 7.28 yuan [1]

| 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-051 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于参加湖北辖区上市公司 2025 年投资者 为进一步加强与投资者的互动交流，塞力斯医疗科技集团股份有限公司（以下简 称"公司"）将参加由中国证券监督管理委员会湖北监管局、湖北省上市公司协会与 深圳市全景网络有限公司联合举办的"2025 年湖北辖区上市公司投资者集体接待日 活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP,参与 本次互动交流，活动时间为 2025 年 6 月 12 日（周四）14:00-16:40。届时公司董事、 副总经理兼董事会秘书范莉女士、财务总监沈燕女士将在线就公司 2024 年度业绩、 公司治理、发展战略、经营状况等投资者关心的问题，与投资者进行沟通与交流，欢 迎广大投资者踊跃参与！ 特此公告。 塞力斯医疗科技集团股份有限公司董事会 ...

Core Viewpoint - The company, Sely Medical, is undergoing significant changes in its funding strategy, including the termination of a specific investment project and the reallocation of remaining funds to enhance liquidity [1][2][3]. Group 1: Company Financials - As of June 6, 2025, Sely Medical's stock closed at 12.18 yuan, down 2.87% from the previous week [1]. - The company's total market capitalization is 2.327 billion yuan, ranking 30th in the pharmaceutical commercial sector and 4723rd in the A-share market [1]. Group 2: Fundraising and Project Updates - The company has fully repaid all funds raised for temporary liquidity support from its 2018 non-public A-share issuance [3]. - Sely Medical plans to terminate the "Expansion of Medical Testing Centralized Marketing and Service Business Scale Project" from its 2018 fundraising, reallocating the remaining 17253.61 million yuan to permanent liquidity support [2][3]. - The decision to terminate the project is attributed to changes in IVD industry policies, market environment shifts, and necessary strategic adjustments by the company [2]. Group 3: Upcoming Events - Sely Medical will hold its third extraordinary general meeting of shareholders on June 20, 2025, to review the proposal regarding the termination of the investment project and the reallocation of funds [2][3].

Core Viewpoint - The company has decided to terminate a fundraising project and permanently supplement the remaining funds into working capital due to changes in market conditions and project feasibility [4][12][20]. Group 1: Board Meeting Details - The fifth board meeting was held on June 4, 2025, with all eight directors present, and all resolutions were passed unanimously [3][6]. - The meeting was conducted in compliance with relevant laws and regulations, ensuring the legality and validity of the resolutions [3]. Group 2: Fundraising Project Termination - The project being terminated is the "Expansion of Medical Testing Integrated Marketing and Service Business Scale Project," with remaining uninvested funds amounting to 172.54 million yuan [12][17]. - The decision to terminate the project was influenced by significant changes in the IVD industry policies and market conditions, which have adversely affected the project's feasibility and profitability [18][20]. - The company has used 437.20 million yuan of the total 625.96 million yuan raised from the 2018 non-public offering as of May 31, 2025 [14]. Group 3: Future Plans for Remaining Funds - The remaining funds of 172.54 million yuan will be permanently supplemented into working capital to enhance the efficiency of fund utilization [19][20]. - This decision aligns with the company's long-term operational development strategy and aims to optimize resource allocation [20]. Group 4: Upcoming Shareholder Meeting - The company plans to hold the third extraordinary general meeting of shareholders on June 20, 2025, to discuss the termination of the fundraising project and the use of remaining funds [8][26]. - The meeting will be conducted both in-person and via an online voting system, ensuring broad participation from shareholders [27][30].

信达证券股份有限公司 关于塞力斯医疗科技集团股份有限公司部分募投项目终止并将 剩余募集资金永久补充流动资金的核查意见 信达证券股份有限公司（以下简称"信达证券"、"保荐机构"）作为塞力 斯医疗科技集团股份有限公司（以下简称"塞力医疗"、"公司"）公开发行可 转换公司债券的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券 交易所股票上市规则》《上市公司监管指引第 2 号——上市公司募集资金管理和 使用的监管要求》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》 等有关规定，就塞力医疗部分募集资金投资项目终止并将剩余募集资金永久补充 流动资金的事项进行了认真、审慎的核查，具体情况如下：： 一、募集资金的基本情况 经中国证券监督管理委员会核发的《关于核准武汉塞力斯医疗科技股份有限 公司非公开发行股票的批复》（证监许可[2017]2322 号）核准，公司于 2018 年 6 月 5 日非公开发行 A 股股票 26,853,709 股，每股面值 1 元，发行价格为每股人 民币 23.31 元，募集资金总额为 625,959,956.79 元，扣除各项发行费用后实际募 集资金净额人民币 607,608 ...